Search

everythinglearnresearchcommunity

for

Search:↓

PRAME helps distinguish between benign and malignant skin cells in most cases.

Monoclonal antibody B72.3 selectively reacts with certain dog tissues, mainly in the gastrointestinal and respiratory tracts.

Certain CD8+ T cells attack hair follicles in alopecia areata, suggesting they could be targeted for treatment.

Genetically at-risk healthy people show similar immune issues as those with Pemphigus vulgaris or Alopecia areata.

Poor response to topical immunotherapy in alopecia areata patients is linked to impaired cell responses.

Monoclonal antibodies LT-1, LT-2, and LT-7 help diagnose certain blood cancers.

New findings suggest targeting IL-23 could treat psoriasis, skin cells can adapt to new roles, direct conversion of skin cells to blood cells may aid cell therapy, removing certain tumor cells could boost cancer immunotherapy, and melanoma may have many tumorigenic cells, not just cancer stem cells.

New imaging technology can show up to 40 different markers in hair loss tissue, helping to understand hair disease better.

TH antibodies in vitiligo and AA patients recognize the same protein parts.

Different people show different symptoms for genetic diseases because of how sensitive their bodies are to small changes in important factors.

Follicular mycosis fungoides can look like a B-cell lymphoma, making diagnosis difficult.

Mycosis fungoides can have unusual symptoms and may be misdiagnosed, but specific cell markers might suggest a lower risk of worsening.

Alopecia areata involves specific immune cells, offering potential treatment targets.

CD3+ T-cell presence is a reliable marker to tell apart alopecia areata from pattern hair loss.

Immunoadsorption successfully treated a man's resistant polymyositis.

Multiphoton microscopy can effectively assess breast cancer treatment responses without labels.

Lipid-antigen stimulation may play a role in folliculotropic mycosis fungoides.

Alopecia areata involves unique activation of certain immune cells.

Different types of atopic dermatitis were linked to specific genetic and immune changes, suggesting that severe cases might need stronger immune-targeting treatments.

Immune checkpoint inhibitors can increase the risk of autoimmune skin diseases, especially bullous pemphigoid.

A new mutation in the STING protein causes a disease with lupus-like symptoms and responds well to a specific inhibitor treatment.

Targeted immunological therapies offer safer and more effective treatments for skin conditions like eczema and psoriasis.

A man developed a skin cancer called folliculotropic mycosis fungoides after a kidney transplant.

Certain immune cells are linked to non-scarring hair loss, suggesting potential for immune-targeted treatments.

The 3D skin model mimics pemphigus vulgaris and helps test treatments.

Local inflammation worsens autoimmune skin conditions by increasing antibody buildup.

Composite biomaterials can precisely control immune responses for better disease treatment.

The antibody created from BCC tissues reacts similarly to both BCC and hair follicles, suggesting BCC may come from hair follicle cells.

A patient with Ivemark syndrome developed mixed type vitiligo after a hepatitis C infection, showing different treatment responses and immune cell involvement in the skin.